In pancreatic cancer, ACTR3 is listed as one of the risk genes associated with liquid-liquid phase separation, and its expression level can be used to construct prognostic models.[23] Research through multi-omics analysis has found that high expression of ACTR3 is associated with high-risk subtypes in pancreatic cancer patients, who exhibit a stronger tendency for immune evasion and lower sensitivity to immunotherapy. This evidence concerns the gene ACTR3 and familial pancreatic carcinoma.